Skip to main content
Top
Published in: Diabetologia 1/2006

01-01-2006 | Editorial

Troglitazone: the lesson that nobody learned?

Author: Edwin A. M. Gale

Published in: Diabetologia | Issue 1/2006

Login to get access

Excerpt

H. G. Wells once wrote a story about a man who travelled in time to a future world. There he encountered members of a beautiful race called the Eloi, who lived carefree lives of sylvan innocence on the surface of the planet, and tried hard to ignore the existence of the Morlocks, an ugly race that lived out of sight under the ground and preyed upon the Eloi for food and slaves. It would of course be too extreme to suggest that this might be taken as a parable of the relationship between the medical profession and the pharmaceutical industry, but there can be no doubt that there are things the medical Eloi prefer not to know, and that the pharmaceutical Morlocks choose not to talk about. The troglitazone story is among them. …
Literature
1.
go back to reference Anonymous (1999) The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623–634CrossRef Anonymous (1999) The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623–634CrossRef
2.
go back to reference Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 346:393–403.CrossRef Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 346:393–403.CrossRef
6.
go back to reference Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl J Med 331:1188–1193PubMedCrossRef Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl J Med 331:1188–1193PubMedCrossRef
14.
go back to reference IMS Health (1998) Business Watch: 1997 at a glance. IMS Health, Fairfield IMS Health (1998) Business Watch: 1997 at a glance. IMS Health, Fairfield
16.
go back to reference Wolfe SM (2000) Letter to the FDA requesting a criminal investigation of Warner Lambert/Parke Davis for what appears to be illegally delaying the submission of data known to the company before troglitazone was marketed. HRG Publication #1515. Public Citizen’s Health Research Group, Washington, 14 March. Available from http://www.citizen.org/publications/print_release.cfm?ID=6716, last accessed in October 2005 Wolfe SM (2000) Letter to the FDA requesting a criminal investigation of Warner Lambert/Parke Davis for what appears to be illegally delaying the submission of data known to the company before troglitazone was marketed. HRG Publication #1515. Public Citizen’s Health Research Group, Washington, 14 March. Available from http://​www.​citizen.​org/​publications/​print_​release.​cfm?​ID=​6716, last accessed in October 2005
17.
go back to reference Graham D, Green L (2000) Memorandum. Final report: Liver failure risk with troglitazone (Rezulin) NDA: 20–720. USDHHS, FDA, Center for Drug Evaluation and Research, Bethesda. 19 December Graham D, Green L (2000) Memorandum. Final report: Liver failure risk with troglitazone (Rezulin) NDA: 20–720. USDHHS, FDA, Center for Drug Evaluation and Research, Bethesda. 19 December
19.
go back to reference Watkins PB, Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. New Engl J Med 338:916–917PubMedCrossRef Watkins PB, Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. New Engl J Med 338:916–917PubMedCrossRef
21.
go back to reference Wolfe SM (1999) Statement before the Food and Drug Administration Endocrine and Metabolic Drugs Advisory Committee meeting advising them to withdraw troglitazone from the U.S. Market. HRG Publication #1476. Public Citizen’s Health Research Group, Washington, 26 March. Available from http://www.citizen.org/publications/release.cfm?ID=6674, last accessed in October 2005 Wolfe SM (1999) Statement before the Food and Drug Administration Endocrine and Metabolic Drugs Advisory Committee meeting advising them to withdraw troglitazone from the U.S. Market. HRG Publication #1476. Public Citizen’s Health Research Group, Washington, 26 March. Available from http://​www.​citizen.​org/​publications/​release.​cfm?​ID=​6674, last accessed in October 2005
23.
go back to reference Gale EAM (2001) Lessons from the glitazones: a story of drug development. Lancet 357:1870–1875 Gale EAM (2001) Lessons from the glitazones: a story of drug development. Lancet 357:1870–1875
24.
go back to reference DeRenzo EG (2005) Conflict-of-interest policy at the National Institutes of Health: the pendulum swings wildly. Kennedy Inst Ethics J 15:199–210PubMedCrossRef DeRenzo EG (2005) Conflict-of-interest policy at the National Institutes of Health: the pendulum swings wildly. Kennedy Inst Ethics J 15:199–210PubMedCrossRef
25.
go back to reference Gale EAM (2003) Between two cultures: the expert clinician and the pharmaceutical industry. Clin Med 3:538–541PubMed Gale EAM (2003) Between two cultures: the expert clinician and the pharmaceutical industry. Clin Med 3:538–541PubMed
Metadata
Title
Troglitazone: the lesson that nobody learned?
Author
Edwin A. M. Gale
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0074-6

Other articles of this Issue 1/2006

Diabetologia 1/2006 Go to the issue

EASD News Section

EASD News Section

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.